DHL is in dis­cus­sions with mul­ti­ple ma­jor drug­mak­ers who are look­ing for the lo­gis­tics com­pa­ny to ei­ther take over their sites or ac­cess its re­sources...

Roche's Genen­tech un­der­went an­oth­er round of lay­offs this week in its ear­ly re­search and de­vel­op­ment group, End­points News has learned, which in­clud­ed shut­ter­ing two re­search...

Bio­phar­ma’s top sci­en­tists and doc­tors don’t make near­ly as much as CEOs, but some still took in eight-fig­ure pay pack­ages in 2025.

As part of...

The cur­rent biotech en­vi­ron­ment can ap­par­ent­ly sup­port an in­dus­try-record IPO and si­mul­ta­ne­ous­ly ham­per ef­forts to raise half a bil­lion dol­lars.

Sum­mit Ther­a­peu­tics ditched plans for...

Para­bilis Med­i­ci­nes' record-break­ing IPOwill be a tough act to fol­low, but a drug de­vel­op­er with three late-stage car­dio med­i­cines is up for the chal­lenge...

Take­da’s $4 bil­lion bet on an oral plaque pso­ri­a­sis drug has paid off again, as the com­pa­ny re­port­ed the pill beat Bris­tol My­ers Squibb’s So­tyk­tu...